Stocktoria
Cell Source, Inc. CLCS
OTC · stock · Pharmaceutical Preparations · website · IPO 2014-01-14
Cell Source, Inc. financials (annual, from 10-K)
Bars are annual figures from 2015 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | — | — | $1.9M | $1.3M | $834,943 | $2.5M | $274,937 | $637,318 | $554,185 | $392,925 |
| SG&A expense | — | — | — | — | — | — | $1.3M | $815,947 | $951,783 | $1.1M |
| Operating income | -$3.8M | -$4.3M | -$4.2M | -$4.0M | -$3.6M | -$3.8M | -$2.0M | -$2.3M | — | — |
| Interest expense | — | — | — | — | $457,371 | $228,842 | -$219,122 | $174,970 | $243,425 | $32,612 |
| Income tax | — | — | — | — | $0 | $0 | — | $0 | $0 | $0 |
| Net income | -$4.5M | -$5.3M | -$5.2M | -$5.5M | -$4.6M | -$4.5M | -$2.1M | -$3.1M | -$967,782 | -$2.5M |
| EPS (diluted) | $-0.14 | $-0.17 | $-0.18 | $-0.19 | — | — | — | — | — | — |
| Operating cash flow | -$2.7M | -$2.3M | -$3.1M | -$3.4M | -$2.8M | -$2.6M | -$2.0M | $2.3M | -$1.5M | $2.0M |
| Cash & equivalents | — | — | $222,665 | $93,095 | $241,619 | $27,908 | $18,934 | $371,048 | $3,735 | $6,944 |
| Total assets | $286,500 | $195,171 | $409,845 | $313,767 | $452,339 | $114,783 | $65,792 | $531,677 | $211,103 | $214,829 |
| Total liabilities | $18.8M | $15.8M | $13.0M | $10.1M | $8.4M | $5.9M | $5.0M | $5.1M | $6.5M | $6.0M |
| Shareholders' equity | -$18.5M | -$15.6M | -$12.6M | -$9.8M | -$7.9M | -$5.7M | -$4.9M | -$4.6M | -$6.2M | -$5.8M |
Source: SEC EDGAR filings · CIK 0001569340 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.